ReviewFrontiers in pharmacology2025
Therapeutic potential of botanical drugs and their metabolites in the treatment of pelvic inflammatory disease.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-Term Dynamics of Pelvic Inflammatory Disease Attributable toInternational journal of women's health · 2026Article
- TNF/NF-κB Signaling Pathway is Involved in Mechanisms of Tongluo Decoction on Rat Models with Sequelae of Pelvic Inflammatory Disease.Journal of inflammation research · 2025Article
- Plant-based bioactives and oxidative stress in reproduction: anti-inflammatory and metabolic protection mechanisms.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of botanical drugs and their metabolites in the treatment of pelvic inflammatory disease (PID) has garnered significant attention. Owing to their broad-spectrum activity, global accessibility, and structural diversity, botanical drugs have emerged as promising candidates for adjunctive or alternative therapies. This review systematically summarizes botanical drugs and their metabolites, focusing on their antimicrobial potential against endogenous and exogenous pathogens associated with PID. Specifically, it addresses various underlying antibacterial mechanisms, including interference with bacterial cell membranes and cell walls, inhibition of pathogen-specific efflux pumps, modulation of pathogen-related gene expression, and synergistic effects when combined with conventional antibiotics. This review highlights the therapeutic promise of botanical drugs and their metabolites, emphasizing critical findings regarding their inhibitory effects on PID-associated pathogens. Such insights provide valuable guidance for future therapeutic strategies and may support ongoing antibiotic discovery and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.